Table 4.
Evidence of cardiovascular risk factors and percentage of participants receiving recommended treatment.
| Cardiovascular Risk Factor | Total N=108 n(%N) | Moderate Risk n=28 (%n) | High Risk n=80 (%n) | Recommended Treatment | n(%N) receiving treatment |
|---|---|---|---|---|---|
| Previous diagnosis heart disease | 16 (14.8) | 2 (7.1) | 14 (17.5) | Antiplatelet therapy | 5 (31.3) |
| Hypertension | 67 (62.0) | 10 (35.7) | 57 (71.3) | Hypertension medication | 60 (89.6) |
| Diabetes mellitus | 47 (43.5) | 20 (71.4) | 27 (33.8) | Diabetes treatment | 37 (78.6) |
| Hyperlipidemia | 83 (76.9) | 11 (39.3) | 72 (90.0) | Lipid lowering medication | 64 (76.8) |
| Cholesterol risk (total cholesterol > 200 mg/ml) | 60 (55.6) | 12 (42.9) | 48 (60.0) | ||
| HDL risk (HDL < 40 mg/ml) | 20 (18.5) | 1 (3.5) | 19(23.8) | Exercise program | 6 (30.0) |
| Current or former smoker | 59 (54.6) | 13(46.4) | 46 (57.5) | Smoking cessation referral | 31 (53.4) |
| * Abnormal cIMT (> 1.0 mm) | 31 (28.7) | 5 (17.9) | 26 (32.5) | None currently indicated | -- |
| * Abnormal ankle- brachial index (ABI ≤.9) | 7 (6.5) | 0 (0.0) | 7 (8.8) | Walking therapy | 4 (57.1) |
| ** History of peripheral vascular disease | 7 (6.5) | 2 (7.1) | 5 (6.3) | ||
| ** Post-menopausal or Hysterectomy | 78 (72.2) | 20 (74.1) | 58 (73.4) | Hormone Replacement Therapy | 41 (52.6) |
*
Modification of Framingham Cardiovascular Risk Profile
**
Not included in risk level calculation